Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2025 Nov 21;16:1701287. doi: 10.3389/fphar.2025.1701287

Correction: Harmine derivative B-9-3 inhibits non-small cell lung cancer via the VEGFA/PI3K/AKT pathway

Yuche Wu 1,2,, Bing Wang 3,, Xuwen Mao 4,, Wei Chen 2, Haji Akber Aisa 1,*
PMCID: PMC12678917  PMID: 41357875

Affiliation 4 ‘Xinjiang Huashidan Pharmaceutical Co., Ltd., Urumqi, Xinjiang, China’ was renumbered as Affiliation 2.

Affiliation 2 was erroneously omitted for author Yuche Wu. The conflict of interest statement has been corrected to “Authors YW and WC were employed by Xinjiang Huashidan Pharmaceutical Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The original article has been updated.

Footnotes

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES